Cargando…
The pharmacokinetics of [(18)F]UCB-H revisited in the healthy non-human primate brain
BACKGROUND: Positron Emission Tomography (PET) imaging of the Synaptic Vesicle glycoprotein (SV) 2A is a new tool to quantify synaptic density. [(18)F]UCB-H was one of the first promising SV2A-ligands to be labelled and used in vivo in rodent and human, while limited information on its pharmacokinet...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026785/ https://www.ncbi.nlm.nih.gov/pubmed/33826008 http://dx.doi.org/10.1186/s13550-021-00777-8 |
_version_ | 1783675694702657536 |
---|---|
author | Goutal, Sébastien Guillermier, Martine Becker, Guillaume Gaudin, Mylène Bramoullé, Yann Luxen, André Lemaire, Christian Plenevaux, Alain Salmon, Eric Hantraye, Philippe Barret, Olivier Van Camp, Nadja |
author_facet | Goutal, Sébastien Guillermier, Martine Becker, Guillaume Gaudin, Mylène Bramoullé, Yann Luxen, André Lemaire, Christian Plenevaux, Alain Salmon, Eric Hantraye, Philippe Barret, Olivier Van Camp, Nadja |
author_sort | Goutal, Sébastien |
collection | PubMed |
description | BACKGROUND: Positron Emission Tomography (PET) imaging of the Synaptic Vesicle glycoprotein (SV) 2A is a new tool to quantify synaptic density. [(18)F]UCB-H was one of the first promising SV2A-ligands to be labelled and used in vivo in rodent and human, while limited information on its pharmacokinetic properties is available in the non-human primate. Here, we evaluate the reliability of the three most commonly used modelling approaches for [(18)F]UCB-H in the non-human cynomolgus primate, adding the coupled fit of the non-displaceable distribution volume (V(ND)) as an alternative approach to improve unstable fit. The results are discussed in the light of the current state of SV2A PET ligands. RESULTS: [(18)F]UCB-H pharmacokinetic data was optimally fitted with a two-compartment model (2TCM), although the model did not always converge (large total volume of distribution (V(T)) or large uncertainty of the estimate). 2TCM with coupled fit K(1)/k(2) across brain regions stabilized the quantification, and confirmed a lower specific signal of [(18)F]UCB-H compared to the newest SV2A-ligands. However, the measures of V(ND) and the influx parameter (K(1)) are similar to what has been reported for other SV2A ligands. These data were reinforced by displacement studies using [(19)F]UCB-H, demonstrating only 50% displacement of the total [(18)F]UCB-H signal at maximal occupancy of SV2A. As previously demonstrated in clinical studies, the graphical method of Logan provided a more robust estimate of V(T) with only a small bias compared to 2TCM. CONCLUSIONS: Modeling issues with a 2TCM due to a slow component have previously been reported for other SV2A ligands with low specific binding, or after blocking of specific binding. As all SV2A ligands share chemical structural similarities, we hypothesize that this slow binding component is common for all SV2A ligands, but only hampers quantification when specific binding is low. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-021-00777-8. |
format | Online Article Text |
id | pubmed-8026785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80267852021-04-27 The pharmacokinetics of [(18)F]UCB-H revisited in the healthy non-human primate brain Goutal, Sébastien Guillermier, Martine Becker, Guillaume Gaudin, Mylène Bramoullé, Yann Luxen, André Lemaire, Christian Plenevaux, Alain Salmon, Eric Hantraye, Philippe Barret, Olivier Van Camp, Nadja EJNMMI Res Original Research BACKGROUND: Positron Emission Tomography (PET) imaging of the Synaptic Vesicle glycoprotein (SV) 2A is a new tool to quantify synaptic density. [(18)F]UCB-H was one of the first promising SV2A-ligands to be labelled and used in vivo in rodent and human, while limited information on its pharmacokinetic properties is available in the non-human primate. Here, we evaluate the reliability of the three most commonly used modelling approaches for [(18)F]UCB-H in the non-human cynomolgus primate, adding the coupled fit of the non-displaceable distribution volume (V(ND)) as an alternative approach to improve unstable fit. The results are discussed in the light of the current state of SV2A PET ligands. RESULTS: [(18)F]UCB-H pharmacokinetic data was optimally fitted with a two-compartment model (2TCM), although the model did not always converge (large total volume of distribution (V(T)) or large uncertainty of the estimate). 2TCM with coupled fit K(1)/k(2) across brain regions stabilized the quantification, and confirmed a lower specific signal of [(18)F]UCB-H compared to the newest SV2A-ligands. However, the measures of V(ND) and the influx parameter (K(1)) are similar to what has been reported for other SV2A ligands. These data were reinforced by displacement studies using [(19)F]UCB-H, demonstrating only 50% displacement of the total [(18)F]UCB-H signal at maximal occupancy of SV2A. As previously demonstrated in clinical studies, the graphical method of Logan provided a more robust estimate of V(T) with only a small bias compared to 2TCM. CONCLUSIONS: Modeling issues with a 2TCM due to a slow component have previously been reported for other SV2A ligands with low specific binding, or after blocking of specific binding. As all SV2A ligands share chemical structural similarities, we hypothesize that this slow binding component is common for all SV2A ligands, but only hampers quantification when specific binding is low. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-021-00777-8. Springer Berlin Heidelberg 2021-04-07 /pmc/articles/PMC8026785/ /pubmed/33826008 http://dx.doi.org/10.1186/s13550-021-00777-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Research Goutal, Sébastien Guillermier, Martine Becker, Guillaume Gaudin, Mylène Bramoullé, Yann Luxen, André Lemaire, Christian Plenevaux, Alain Salmon, Eric Hantraye, Philippe Barret, Olivier Van Camp, Nadja The pharmacokinetics of [(18)F]UCB-H revisited in the healthy non-human primate brain |
title | The pharmacokinetics of [(18)F]UCB-H revisited in the healthy non-human primate brain |
title_full | The pharmacokinetics of [(18)F]UCB-H revisited in the healthy non-human primate brain |
title_fullStr | The pharmacokinetics of [(18)F]UCB-H revisited in the healthy non-human primate brain |
title_full_unstemmed | The pharmacokinetics of [(18)F]UCB-H revisited in the healthy non-human primate brain |
title_short | The pharmacokinetics of [(18)F]UCB-H revisited in the healthy non-human primate brain |
title_sort | pharmacokinetics of [(18)f]ucb-h revisited in the healthy non-human primate brain |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026785/ https://www.ncbi.nlm.nih.gov/pubmed/33826008 http://dx.doi.org/10.1186/s13550-021-00777-8 |
work_keys_str_mv | AT goutalsebastien thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT guillermiermartine thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT beckerguillaume thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT gaudinmylene thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT bramoulleyann thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT luxenandre thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT lemairechristian thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT plenevauxalain thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT salmoneric thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT hantrayephilippe thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT barretolivier thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT vancampnadja thepharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT goutalsebastien pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT guillermiermartine pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT beckerguillaume pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT gaudinmylene pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT bramoulleyann pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT luxenandre pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT lemairechristian pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT plenevauxalain pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT salmoneric pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT hantrayephilippe pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT barretolivier pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain AT vancampnadja pharmacokineticsof18fucbhrevisitedinthehealthynonhumanprimatebrain |